Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan-Feb;1(1):41-8.
doi: 10.4161/mabs.1.1.7509.

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

Melarkode S Ramakrishnan  1 , Anand Eswaraiah, Tania Crombet, Patricia Piedra, Giselle Saurez, Harish Iyer, A S Arvind
Affiliations
Review

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

Melarkode S Ramakrishnan et al. MAbs. 2009 Jan-Feb.

Abstract

Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This review focuses on the unique functional characteristics of nimotuzumab. Also, it discusses the safety and efficacy data obtained from the Phase IIb clinical trial conducted in India in SCCHN. Post marketing surveillance data from Cuba for the use of nimotuzumab in pediatric and adult glioma is also discussed. Overall, nimotuzumab has immense therapeutic potential in cancers of epithelial origin.

Keywords: EGFR; SCCHN; glioma; humanized; monoclonal antibody; nimotuzumab; overall survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Enrollment, randomization and follow-up of patients in the study.
Figure 2
Figure 2
Comparison of progression free survival of nimotuzumab + CT + RT and CT + RT arm.
Figure 3
Figure 3
Comparison of disease free survival of nimotuzumab + CT + RT and CT + RT arm.
Figure 4
Figure 4
Comparison of overall survival of nimotuzumab + CT + RT and CT + RT arm.
Figure 5
Figure 5
Comparison of progression free survival of nimotuzumab + RT and RT arm.
Figure 6
Figure 6
Comparison of disease free survival of nimotuzumab + RT and RT arm.
Figure 7
Figure 7
Comparison of overall survival of nimotuzumab + RT and RT arm.
See this image and copyright information in PMC

References

    1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New Engl J Med. 2008;358:1160–1174. - PubMed
    1. Speake G, Holloway B, Costello G. Recent developments related to the EGFR as a target for cancer chemotherapy. Curr Opin Pharmacol. 2005;5:343–349. - PubMed
    1. Hynes NE, Lane HA. Errb receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–354. - PubMed
    1. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev. 2004;30:255–268. - PubMed
    1. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology. 1997;3:71–78. - PubMed

MeSH terms